Who are Climb Bio, Inc.'s main suppliers?

Climb Bio, Inc. (CLYM) key suppliers include: RA-CAPITAL-MANAGEMENT-L-P, OPPENHEIMER-CO-INC, BEIJING-MABWORKS-BIOTECH-CO-LTD. View the full supplier network at chainsifter.com/chain/CLYM.

Who are Climb Bio, Inc.'s major customers?

Climb Bio, Inc. (CLYM) key customers include: RA-CAPITAL-MANAGEMENT-L-P. View the full customer network at chainsifter.com/chain/CLYM.

What sector is Climb Bio, Inc. in?

Climb Bio, Inc. (CLYM) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

CLYM Supply Chain: Climb Bio, Inc. Supplier List & 6 Relationships

3Suppliers

1Customers

2Debt Items

20Related Chains

Climb Bio, Inc. Suppliers

Ticker	Name	Confidence	Evidence
RA-CAPITAL-MANAGEMENT-L-P	RA-CAPITAL-MANAGEMENT-L-P	92%	the Company agreed to issue and sell to the Investors in a private placement an aggregate of 9,481,000 shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), at a price of …
OPPENHEIMER-CO-INC	OPPENHEIMER-CO-INC	90%	In March 2025, we entered into an Equity Distribution Agreement (the Distribution Agreement) with Oppenheimer & Co. Inc., as agent (Oppenheimer), pursuant to which we may offer and sell shares of our…
BEIJING-MABWORKS-BIOTECH-CO-LTD	BEIJING-MABWORKS-BIOTECH-CO-LTD	85%	the ability of the Company to timely and successfully achieve or recognize the anticipated benefits of its technology transfer and exclusive license agreement with Beijing Mabworks Biotech Co., Ltd.

Climb Bio, Inc. Customers

Ticker	Name	Confidence	Evidence
RA-CAPITAL-MANAGEMENT-L-P	RA-CAPITAL-MANAGEMENT-L-P	92%	the Company agreed to issue and sell to the Investors in a private placement an aggregate of 9,481,000 shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), at a price of …

Climb Bio, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
CLYM-DEBT-8715	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2021-12-31.
CLYM-DEBT	Debt stack $541,000	90%	Market cache reports total debt of $541,000.

Climb Bio, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Climb Bio, Inc..

Climb Bio, Inc. Ownership

Holder	Name	Confidence	Evidence
CLYM-OWNER-RA-CAPITAL-MANAGEMENT-L-P	RA CAPITAL MANAGEMENT, L.P.	90%	13F overlay lists RA CAPITAL MANAGEMENT, L.P. as top holder; 83 tracked holders.

Climb Bio, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
HALO	Halozyme Therapeutics, Inc.	100.00	2
HOWL	Werewolf Therapeutics, Inc.	100.00	2
GDTC	CytoMed Therapeutics Limited	100.00	2
GILD	Gilead Sciences, Inc.	100.00	2
AXSM	Axsome Therapeutics, Inc.	100.00	2
BMY	Bristol-Myers Squibb Company	100.00	2
COLL	Collegium Pharmaceutical, Inc.	100.00	2
BMYMP	Bristol-Myers Squibb Co	100.00	2
BHC	Bausch Health Companies Inc.	100.00	2
DAWN	Day One Biopharmaceuticals Inc	100.00	2
DNTH	Dianthus Therapeutics, Inc.	100.00	2
VERA	Vera Therapeutics, Inc.	100.00	1	['receiving']
AZN	AstraZeneca PLC	100.00	2
CLLS	Cellectis S.A.	100.00	2
AVBP	ArriVent BioPharma, Inc.	100.00	2
CRSP	CRISPR Therapeutics AG	100.00	2
AUPH	Aurinia Pharmaceuticals Inc.	100.00	2
ARTV	Artiva Biotherapeutics, Inc.	100.00	2
FDMT	4D Molecular Therapeutics, Inc.	100.00	2
INCY	Incyte Corporation	100.00	2

Climb Bio, Inc. Supply Chain